LDAH

Across TCGA pan-cancer cohorts, LDAH mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated LDAH data layer compared with 25 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher LDAH mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated LDAH expression acts as an unfavorable survival marker, although some lineages such as CCRCC and COAD show a favorable association.

CCRCC, COAD, and LUAD are the cancer types where LDAH mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	1.000	0.890	.003	47	view →
COAD	DFS	Median	III,IV	1.000	0.835	.032	24	view →
LUAD	OS	Tertile	All	0.576	0.852	.004	21	view →
GBM	OS	Median	All	0.729	0.901	.005	6	view →
LSCC	DFS	Median	II,III,IV	0.485	1.000	.006	6	view →
PDAC	DFS	Median	II,III,IV	0.637	0.810	.037	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

LDAH–CCRCC (OS)

Open the CCRCC breakdown →